Clinical trials play a crucial role in expanding what we know about #FoodAllergy care in young children, where treatment options remain limited. Right now, important research is being conducted at clinical trial sites across the globe for COMFORT Toddlers, a supplemental safety

Teachers, parents and caregivers: Are you ready for students heading back to school? Take our quick quiz to test your knowledge on #FoodAllergies in the classroom. Education and awareness make all the difference!

Our CEO, Daniel Tassé, will be in New York for the H.C. Wainwright 27th Annual Global Investment Conference, where he will participate in a #FiresideChat on Tuesday, September 9 at 11:30am ET. We look forward to engaging with investors and industry peers as we continue

In recent open-label extension studies evaluating our investigational lead product candidate, sustained treatment showed continued increases in treatment effect over three years. These results highlight the potential of a gradual approach to progressive desensitization, where

At DBV, our company culture is built on four core values that we call the 4C’s: Curiosity, Courage, Collaboration, and Credibility. In this employee spotlight, team members share which “C” resonates most with them and why. This week, we’re highlighting Jessica Raiz, Vice

We’re excited to be at the FAACT Allergy Summit this week in Oak Brook, IL! This event brings together allergy advocates, influencers, patients, caregivers and organizations all committed to advancing care and support for the #FoodAllergy community. We look forward to being a

At DBV Technologies, we’re working to develop a non-invasive, disease modifying approach to #PeanutAllergy based on epicutaneous immunotherapy (EPIT). Our goal is to re-educate the immune system to reduce the risk of accidental exposure reactions. Learn more:

#DYK, allergic reactions to peanuts and tree nuts spike as much as 85% on Halloween? With 1 in 13 children living with #FoodAllergies, we all have a role in keeping trick-or-treaters safe. Thoughtful planning and preparation can lower risks and help families feel secure. At DBV

We’re heading to the #FARE Food Allergy Summit in Washington D.C.! From October 30 – November 1, #OctoberFARE brings together the annual FARE Food Allergy Summit, FARE Neighborhoods Day, and Clinical Development Day, plus a special Teal Pumpkin Halloween Bash for #FARE’s

Today, we reported third quarter 2025 financial results. Read the full press release here: bit.ly/4oluuM4

We’re excited to participate in the ACAAI Annual Scientific Meeting and share new insights in pediatric food allergy care. Connect with us at: 📍Our product theater on the benefits of earlier intervention, where we’ll announce a planned Phase 2 study in peanut-allergic infants.

We’re thrilled to announce the appointment of Philina Lee to our Board of Directors. Her proven record of leading high-growth organizations through commercialization is invaluable at this stage of DBV’s evolution. Learn more about Philina here: bit.ly/4hI9Cfd

Welcome Kevin Trapp, our Chief Commercial Officer! In his new role, Kevin will lead all aspects of DBV’s global commercial strategy and execution, supporting the company’s mission to advance innovative solutions for the food allergy community. Learn more about Kevin here:

Are you attending the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston next week? Our CEO, Daniel Tassé, will participate in a #FiresideChat on Tuesday, November 11, at 2:00 p.m. ET View presentation details to learn more: bit.ly/439FBiA

It was great to be part of the #ACAAI2025 Annual Scientific Meeting! Our team had the opportunity to connect with the allergy community, engage in thoughtful discussions about the benefits of early intervention, and share insights on how we’re advancing pediatric #FoodAllergy

Calling all peanut allergy families 📢 we want to hear from you! We’re looking for passionate patients and caregivers in the #FoodAllergy community to share their experiences with #PeanutAllergy. Together, we can help raise awareness, drive change, and support families facing

#DYK? Roughly 75% of peanut-allergic children will never outgrow their allergy in their lifetime, leaving millions of families searching for solutions. At DBV Technologies, we understand that early action may impact food allergy outcomes – that’s why we are focused on advancing

Happy Thanksgiving from the DBV Technologies team! As families gather this season, we’re reminded of the importance of inclusion and awareness for those living with food allergies. At DBV, we remain committed to advancing early intervention and supporting the food allergy

#ICYMI, catch up on recent headlines featuring end-of-study data on the long-term efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers, and our planned Phase 2 study in infants with #PeanutAllergy. Pieces by @HealthDay, @Allergic Living, and Healio

At DBV, we’re proud to spotlight the culture that drives our commitment to making a difference for families living with #FoodAllergies and other immunological diseases. In our latest spotlight, Robert Pietrusko, Chief Regulatory Officer, reflects on what working toward a